Informações:
Falhas:
ID
16792
Descrição
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine; ODM derived from: https://clinicaltrials.gov/show/NCT00518427
Link
https://clinicaltrials.gov/show/NCT00518427
Palavras-chave
Versões (1)
- 07/08/2016 07/08/2016 -
Transferido a
7 de agosto de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Diabetes Type 2 NCT00518427
Eligibility Diabetes Type 2 NCT00518427
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Type 2 NCT00518427
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Type 2 diabetes inadequately controlled on a combination of oad + nph insulin
Item
patients with type 2 diabetes inadequately controlled on a combination of oad + nph insulin for more than three months
boolean
C0011860 (UMLS CUI [1])
C0860160 (UMLS CUI [2,1])
C0021658 (UMLS CUI [2,2])
C0860160 (UMLS CUI [3,1])
C0359086 (UMLS CUI [3,2])
C0860160 (UMLS CUI [2,1])
C0021658 (UMLS CUI [2,2])
C0860160 (UMLS CUI [3,1])
C0359086 (UMLS CUI [3,2])
Stable oad therapy
Item
stable oad therapy for at least three months, according to the following specified daily dose: glibenclamide> 3, 5 mg, glipizid >5 mg, glimepiride >2mg, metformin>1000 mg, acarbose >150 mg
boolean
C0017628 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0017642 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0061323 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0025598 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0050393 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0178602 (UMLS CUI [1,2])
C0017642 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0061323 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0025598 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0050393 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
HbA1C
Item
hba1c > 7,0%
boolean
C0202054 (UMLS CUI [1])
ability to perform qol assessment
Item
ability to perform qol assessment
boolean
C1321605 (UMLS CUI [1,1])
C0281588 (UMLS CUI [1,2])
C0281588 (UMLS CUI [1,2])
BMI
Item
body mass indes: women <30 and men <32
boolean
C1305855 (UMLS CUI [1])
Autoimmune diabetes
Item
autoimmune diabetes, as defined by who
boolean
C0205734 (UMLS CUI [1])
Thiazolidinedione
Item
ongoing treatment with thiazolidinedione drug
boolean
C1257987 (UMLS CUI [1])
Retinopathy with surgical treatment
Item
retinopathy with surgical treatment during preceding three months of study entry or requiring treatment within three months after study entry
boolean
C0011884 (UMLS CUI [1,1])
C0543467 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,2])
Drug abuse
Item
drug abuse
boolean
C0038586 (UMLS CUI [1])
hypersensitivity to insulin glagine excipients
Item
hypersensitivity to insulin glagine excipients
boolean
C0020517 (UMLS CUI [1,1])
C0907402 (UMLS CUI [1,2])
C0907402 (UMLS CUI [1,2])
Study Subject Participation Status
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])